Comparison between A & M Febcon IPO and ANG Lifesciences IPO.
A & M Febcon IPO is a SME Fixed Price IPO proposed to list at BSE SME while ANG Lifesciences IPO is a SME Fixed Price proposed to list at BSE SME.
| A & M Febcon IPO | ANG Lifesciences IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Gretex Corporate Services Ltd. | Oneview Corporate Advisors Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Gretex Share Broking Pvt.Ltd. | Guiness Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of A & M Febcon IPO is up to ₹6.34 Cr whereas the issue size of the ANG Lifesciences IPO is up to ₹11.39 Cr. The final issue price of A & M Febcon IPO is ₹18.00 per share and of ANG Lifesciences IPO is ₹80.00 per share.
| A & M Febcon IPO | ANG Lifesciences IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Final) | ₹18.00 per share | ₹80.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Market Lot Size | 8000 shares | 1600 shares |
| Fresh Issue Size | 35,20,000 shares | 14,24,000 shares |
| Fresh Issue Size (Amount) | up to ₹6.34 Cr | up to ₹11.39 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 35,20,000 shares | 14,24,000 shares |
| Issue Size Total (Amount) | up to ₹6.34 Cr | up to ₹11.39 Cr |
A & M Febcon IPO opens on Sep 01, 2017, while ANG Lifesciences IPO opens on Aug 29, 2017. The closing date of A & M Febcon IPO and ANG Lifesciences IPO is Sep 06, 2017, and Aug 31, 2017, respectively.
| A & M Febcon IPO | ANG Lifesciences IPO | |
|---|---|---|
| Issue Open | Sep 01, 2017 | Aug 29, 2017 |
| Issue Close | Sep 06, 2017 | Aug 31, 2017 |
| Basis Of Allotment (Tentative) | Sep 11, 2017 | |
| Listing date (Tentative) | Sep 14, 2017 | Sep 08, 2017 |
A & M Febcon IPO P/E ratio is , as compared to ANG Lifesciences IPO P/E ratio of .
| A & M Febcon IPO | ANG Lifesciences IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 97.60% | 99.94% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 53.66% | 71.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹16.47 Cr. | ₹41.47 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the A & M Febcon IPO Retail Individual Investors (RII) are offered 17,60,000 shares while in ANG Lifesciences IPO retail investors are offered 17,60,000 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in A & M Febcon IPO and 0 shares in ANG Lifesciences IPO.
| A & M Febcon IPO | ANG Lifesciences IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 1,92,000 shares | 76,800 shares |
| QIB | 0 shares | 0 shares |
| NII | 17,60,000 shares | 7,12,000 shares |
| RII | 17,60,000 shares | 7,12,000 shares |
| Employee | 0 shares | 0 shares |
| Total | 35,20,000 shares | 14,24,000 shares |
A & M Febcon IPO subscribed 1.51x in total, whereas ANG Lifesciences IPO subscribed 8.25x.
| A & M Febcon IPO | ANG Lifesciences IPO | |
|---|---|---|
| NII (times) | 0.30x | 5.13x |
| RII (times) | 2.73x | 11.36x |
| Total (times) | 1.51x | 8.25x |
